ClinicalTrials.gg

Program

ibutamoren

Also written as “LUM-201” and “MK0677”.

Its studies are mostly in Dwarfism, Pituitary · Obesity · Hip Fractures · Alzheimer Disease, led by 2 companies.

Furthest: phase 3, since Apr 21, 20259 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lumos Pharma75 open or runningphase 3since Apr 21, 2025Oct 26, 2020Dec 2027phase 3 · NCT06948214
Merck20 open or runningphase 2since Dec 15, 2003Dec 15, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2003First study: phase 2 study in Alzheimer DiseaseNew to MerckMerck · NCT00074529 · 512 enrolled
  2. Aug 5, 2005Phase 2 study in Hip FracturesMerck · NCT00128115 · 83 enrolled · Germany, Norway, Spain and more
  3. Oct 26, 2020Lumos Pharma's first study: phase 2 study in Dwarfism, PituitaryNew to Lumos PharmaLumos Pharma · NCT04614337 · 104 enrolled · United States, Australia, Israel and more
  4. Mar 17, 2021Phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT04806854 · 24 enrolled · Chile
  5. Feb 10, 2022Phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT05250063 · 15 enrolled · United States, Poland
  6. Mar 19, 2023Phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT05796440 · 60 planned · United States, Australia
  7. Apr 21, 2025Phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT06948214 · 150 planned · United States, Argentina, Australia and more
  8. Aug 5, 2025Phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT07129759 · 150 planned
  9. Jul 9, 2026Phase 2 study in ObesityLumos Pharma · NCT07754045 · 202 planned

Ahead

  1. Dec 2027Primary completion: phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT06948214
  2. Feb 15, 2028Primary completion: phase 2 study in ObesityLumos Pharma · NCT07754045
  3. Mar 2028Primary completion: phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT05796440
  4. Feb 2030Primary completion: phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT07129759

TargetBeta

GHSR →read by rule
“Ghrelin receptor agonist”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07754045Obesity2Not yet recruitingLumos PharmaFeb 15, 2028202
NCT07129759Dwarfism, Pituitary3Not yet recruitingLumos PharmaFeb 2030150
NCT06948214Dwarfism, Pituitary · United States, Argentina, Australia and more3RecruitingLumos PharmaDec 2027150
NCT05796440Dwarfism, Pituitary · United States, Australia2By invitationLumos PharmaMar 202860
NCT05250063Dwarfism, Pituitary · United States, Poland2CompletedLumos PharmaJan 22, 202515
NCT04806854Dwarfism, Pituitary · Chile2Active, not recruitingLumos PharmaApr 203024
NCT04614337Dwarfism, Pituitary · United States, Australia, Israel and more2CompletedLumos PharmaSep 4, 2024104
NCT00128115Hip Fractures · Germany, Norway, Spain and more2TerminatedMerckAug 200783
NCT00074529Alzheimer Disease2CompletedMerckJan 2006512

How it is read

Names in the registry

  • “LUM-201”, 7 entries
  • “MK0677”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.